AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6362125
Drug: Albendazole (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (three consecutive days at the same daily dose level)
Trial: 10779814
Drug: 20 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg/kg oral granisetron solution
Trial: 10779814
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of granisetron (20 microg/kg and 40 microg/kg)
Trial: 8773915
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (primed continuous infusion from t = 1 h to t = 5 h)
Trial: 8773915
Drug: No amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No amino acid infusion (control group)
Trial: 20167702
Drug: Avosentan 25
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avosentan 25 mg/d
Trial: 20167702
Drug: Avosentan 50
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avosentan 50 mg/d
Trial: 15956269
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg/day combined with sertraline 100 mg/day and psychosocial support
Trial: 15956269
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with sertraline 100 mg/day and psychosocial support
Trial: 11931398
Drug: Once-weekly 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly 600 mg rifapentine + 15 mg/kg isoniazid (HRp1)
Trial: 11931398
Drug: Thrice-weekly isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thrice-weekly isoniazid + rifampicin (HR3)
Trial: 9815520
Drug: Clodronate 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1,600 mg orally per day for 2 years
Trial: 7655833
Drug: ICE regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE regimen (cisplatin: 20 mg/m2 x day x 5, ifosfamide: 1.8 g/m2 x day x 5, mesna: 1.2 g/m2 x day x 5, etoposide: 100 mg/m2 x day x 5)
Trial: 7655833
Drug: CE regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE regimen (cisplatin: 20 mg/m2 x day x 5, etoposide: 100 mg/m2 x day x 5)
Trial: 2462343
Drug: Encainide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide administered twice daily (group A)
Trial: 2462343
Drug: Encainide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide administered three times daily (group B)
Trial: 29481979
Drug: 0, 6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0, 6, 12, or 18 sessions of spinal manipulative therapy (SMT)
Trial: 26843373
Drug: TAU (treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (treated as usual with antipsychotics)
Trial: 16000606
Drug: Adjuvant cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant cisplatin-based chemotherapy (300-400 mg/m2) for 3-4 cycles
Trial: 20978195
Drug: Adjuvant cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant cisplatin-based chemotherapy
Trial: 12873248
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day dexamphetamine (n = 16)
Trial: 2065826
Drug: Antituberculous drugs
RxNorm normalized name: ANTITUBERCULARS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculous drugs only
Trial: 2065826
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide and furosemide in addition to antituberculous treatment
Trial: 6406460
Drug: Bupropion (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (12.5 mg to 100 mg)
Trial: 22794217
Drug: 2 mg/mL
RxNorm normalized name: urea 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/mL berberine
Trial: 318908
Drug: Butorphanol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 2.0 mg
Trial: 2020612
Drug: Butorphanol 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 3.0 mg
Trial: 2020612
Drug: Butorphanol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (all doses)
Trial: 20520283
Drug: Haloperidol 4
RxNorm normalized name: haloperidol 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 4 mg BID
Trial: 21755540
Drug: Asenapine 10
RxNorm normalized name: asenapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 10 mg BID
Trial: 10622345
Drug: Fluoxetine (FLU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FLU), 20 mg QD for 11 weeks
Trial: 2019135
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and conventional amino acid solution
Trial: 2019135
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and branch-chain amino acid enriched solution
Trial: 2019135
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusions
Trial: 7046898
Drug: Chlorpromazine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (300 mg to 2100 mg)
Trial: 7046898
Drug: Pimozide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (10 to 70 mg)
Trial: 21211560
Drug: Polyherbal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyherbal formulation (Geriforte tablets)
Trial: 9056163
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg p.o./d/2 weeks/3 months)
Trial: 9056163
Drug: Calcidiol (32,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcidiol (32,000 IU/weekly)
Trial: 8368227
Drug: Pamidronate 30
RxNorm normalized name: pamidronate 30 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 30 mg
Trial: 8368227
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg
Trial: 23078156
Drug: HBD3 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBD3 peptide gel
Trial: 17258626
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gel (CHX)
Trial: 23078156
Drug: Mismatched peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mismatched peptide gel (MP)
Trial: 18458163
Drug: Salt tablets
RxNorm normalized name: bile salts Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt tablets (200 mmol/d of sodium)
Trial: 29576001
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg per day)
Trial: 26367217
Drug: melphalan 200
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: melphalan 200 mg/m² (mel200)
Trial: 24375768
Drug: Alisporivir (ALV)
RxNorm normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir (ALV) 1000 mg once-daily
Trial: 24375768
Drug: Alisporivir (ALV)
RxNorm normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir (ALV) 400 mg with RBV 400 mg twice-daily for 36 weeks
Trial: 24375768
Drug: Response-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-guided treatment
Trial: 12401850
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline 200 mg b.d. 24 h before and for 48 h after CAG
Trial: 2792172
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of frusemide without plasma volume expansion
Trial: 2792172
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of dextran
Trial: 88754
Drug: Chemotherapy (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (methotrexate 400 mg followed by citrovorum factor 100 mg + bleomycin 60 mg/week for the first 15 weeks)
Trial: 88754
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Chemotherapy, Immunotherapy, No treatment)
Trial: 21471550
Drug: Tramadol/paracetamol (37.5+325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/paracetamol (37.5+325 mg)
Trial: 21471550
Drug: Paracetamol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol monotherapy (1000 mg)
Trial: 19258386
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (LP: 0.6-0.8 g/kg IBW/day)
Trial: 16750450
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone ER 10 mg q12h
Trial: 29297732
Drug: Canagliflozin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (100 mg or 300 mg)
Trial: 29297732
Drug: Canagliflozin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (100 mg with possible increase to 300 mg)
Trial: 27300645
Drug: ONO-9054 10
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-9054 10 μg/mL
Trial: 7729019
Drug: Medical group
RxNorm normalized name: ALCOHOL 266.1615 mL in 354.882 mL TOPICAL GEL [Iconic Medical Group Hand Sanitizer - 12oz 12oz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical group (nonsurgical therapy)
Trial: 7426351
Drug: Influenza virus
RxNorm normalized name: Influenza virus Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza virus RIT 4050 (H3N2) vaccine
Trial: 21563871
Drug: Milk supplemented
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplemented with 5 ppm fluoride and probiotic bacteria (Lactobacillus rhamnosus LB21, 10^7 CFU/mL)
Trial: 31862830
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment alone (ST group)
Trial: 20516439
Drug: MP-T (melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP-T (melphalan plus prednisone plus thalidomide 200 mg/d)
Trial: 10606935
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (n = 6)
Trial: 6432417
Drug: Auranofin 6
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auranofin 6 mg/day
Trial: 6432417
Drug: D-penicillamine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine 500 mg/day
Trial: 28099485
Drug: AS03-adjuvanted H5N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H5N1 vaccine
Trial: 17302879
Drug: DHEA 50-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50-mg
Trial: 14759617
Drug: NuvaRing with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuvaRing with a single dose of antimycotic
Trial: 3130256
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (VPA) 500 mg t.i.d. for 5 days
Trial: 3130256
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (VPA) in epileptic patients on established monotherapy
Trial: 26556955
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and ropivacaine
Trial: 8211671
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation with a dose per fraction of 2 Gy
Trial: 8211671
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation with a dose per fraction of 3 Gy
Trial: 8211671
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation with a dose per fraction of 4 Gy
Trial: 8211671
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation with a dose per fraction of 5.4 Gy
Trial: 2869723
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dezocine
Trial: 29856817
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH), 5000 IU twice daily
Trial: 25296661
Drug: Flurbiprofen 8.75
RxNorm normalized name: flurbiprofen 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 8.75 mg lozenge
Trial: 15688086
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg ghrelin (i.v. bolus injection)
Trial: 12441831
Drug: Alfentanil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil and ketamine infusions targeting plasma concentrations of 75 ng/ml for alfentanil and 150 ng/ml for ketamine
Trial: 31673898
Drug: Carfilzomib in
RxNorm normalized name: carfilzomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib in combination with lenalidomide and dexamethasone (KRd)
Trial: 30109404
Drug: 4-ml hyaluronic
RxNorm normalized name: rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4-ml hyaluronic acid treatment
Trial: 30109404
Drug: SVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVF treatment
Trial: 24800919
Drug: 6-mercaptopurine capsules
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine capsules
Trial: 18751689
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily (40QD)
Trial: 18751689
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg twice daily (20TD)
Trial: 17900462
Drug: Carotid‐derived augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid‐derived augmentation index
Trial: 15006018
Drug: budesonide/formoterol adjustable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/formoterol adjustable maintenance dosing (AMD)
Trial: 8030598
Drug: Complete L-amino
RxNorm normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complete L-amino acid mixture diet (group 3)
Trial: 31407937
Drug: Interpersonal Therapy‐Adolescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Therapy‐Adolescent Skills Training
Trial: 28225835
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose of mulberry-extract (Reducose)
Trial: 28225835
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose of mulberry-extract (Reducose)
Trial: 28225835
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of mulberry-extract (Reducose)
Trial: 8103611
Drug: Oral sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sotalol treatment (pre- and postoperative)
Trial: 8103611
Drug: Routine beta-blocking
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine beta-blocking treatment (half the preoperative dose)
Trial: 3029592
Drug: Initial radiotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial radiotherapy plus chemotherapy
Trial: 3029592
Drug: Delayed radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed radiotherapy plus chemotherapy
Trial: 30737932
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment with poor quality root filling and poor quality crown restoration (PE + PR)
Trial: 30737932
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment with root posts
Trial: 30737932
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment without root posts
Trial: 24168514
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral isotretinoin (ISO), 20 mg/day for six months
Trial: 12572927
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg of intravenous L-carnitine at the end of each hemodialysis treatment (Group A)
Trial: 10601747
Drug: Discourse-dependent semantic
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discourse-dependent semantic anomalies (e.g., 'slow')
Trial: 30969260
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa (daily subcutaneous injections)
Trial: 29716784
Drug: Emixustat 5
RxNorm normalized name: Emixustat
DrugBank: Emixustat (DB12608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emixustat 5 mg
Trial: 29716784
Drug: Emixustat 10
RxNorm normalized name: Emixustat
DrugBank: Emixustat (DB12608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emixustat 10 mg
Trial: 9394172
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus exposure to pulsed magnetic fields (PMF) for four weeks (sinusoidal form, 0.95 to 1.05 Hz, amplitude +/- 2400 nano Teslas)
Trial: 22978771
Drug: Quetiapine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (750 mg/day)
Trial: 20162509
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 3 weeks (n = 20)
Trial: 16142551
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin chloride 10 mg/day
Trial: 16142551
Drug: Extended-release tolterodine
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tolterodine tartrate 4 mg/day
Trial: 8949620
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg and caffeine 50 mg
Trial: 8949620
Drug: Paracetamol 400
RxNorm normalized name: Hydrocodone bitartrate 5 mg and paracetamol 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 400 mg and dextropropoxyphene 30 mg
Trial: 7178370
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg i.v.)
Trial: 27001374
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of two implants supporting mandibular overdentures (T3)
Trial: 26023213
Drug: 8‐week Internet‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8‐week Internet‐based pain coping skills training (PCST) protocol in addition to a 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Trial: 26023213
Drug: 24‐week standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Trial: 17634479
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in EGFR low group (n = 113)
Trial: 17634479
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in EGFR high group (n = 73)
Trial: 8210253
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) administered by drip infusion for 2 hours (group A)
Trial: 3513884
Drug: Imipramine 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 250 mg for four weeks
Trial: 25170796
Drug: Trospium 30
RxNorm normalized name: trospium 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium 30 mg/day + Solifenacin 10 mg/day
Trial: 20196149
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) therapy
Trial: 18554862
Drug: 17-beta-estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-beta-estradiol (2 mg/day)